{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-24-028366","form_type":"8-K","ticker":"IMCR","cik":"0001671927","company_name":"Immunocore Holdings plc","filed_at":"2024-05-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.514406+00:00","generated_at":"2026-06-01T07:11:48.075266+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Immunocore reports Phase 1 brenetafusp data: 56% disease control in checkpoint pre-treated melanoma","bullets":["Brenetafusp monotherapy in 47 late-line cutaneous melanoma patients showed 56% DCR (4 PR, 16 SD) and 4.2 months median PFS in PRAME+ patients.","ctDNA molecular response in 42% of PRAME+ patients; trend for longer PFS/OS in molecular responders.","Combination with pembrolizumab well tolerated; 4/7 evaluable patients achieved disease control including 1 ongoing PR.","T cell fitness gene signature: high expression associated with 6-month median PFS and 69% DCR vs 2 months/42% for low.","Phase 3 PRISM-MEL-301 trial (brenetafusp + nivolumab) enrolling first-line advanced melanoma patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-24-028366","json":"https://secwatch.observer/filing/0001140361-24-028366.json","markdown":"https://secwatch.observer/filing/0001140361-24-028366.md","text":"https://secwatch.observer/filing/0001140361-24-028366.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124028366/0001140361-24-028366-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671927/000114036124028366/ef20030354_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T07:11:48.075266+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}